Compounded Tirzepatide, and Why Its Legal Basis Closed First
Compounded tirzepatide existed because of a shortage. That shortage was declared over in December 2024, the compounders challenged it and lost, and the transition period ran out months before semaglutide’s did.
- 730+Adverse event reports the FDA has received, and says are likely underreported
- 19 Dec 2024The day the FDA determined the tirzepatide shortage was resolved
- DeniedThe compounders’ injunction, in court, on 5 March 2025
- Not listedTirzepatide is on neither the shortage list nor the 503B bulks list
Regulatory status
Compounded tirzepatide is not an FDA-approved product and never was. The shortage that permitted compounding copies of it ended in December 2024, and the transition periods expired in early 2025. The FDA’s own page states that tirzepatide appears on neither its drug shortage list nor the 503B bulks list.
The short version
Federal law lets compounders make copies of an approved drug while that drug is in shortage. That is the entire legal foundation compounded tirzepatide rested on. Remove the shortage and the foundation goes with it.
This is the part that distinguishes tirzepatide from compounded semaglutide, which is otherwise a very similar story. Tirzepatide’s shortage was declared resolved first, its wind-down deadlines fell roughly two months earlier, and the compounders’ attempt to block the decision in court was refused. Semaglutide’s timeline ran behind it at every step.
None of this is a claim that compounded tirzepatide does not work, or that everyone taking it has been harmed. It is a description of where the legal ground went, and what the FDA has recorded since.
How the window opened and closed
Every date below is from the FDA’s own statement page, which records each step as it happened rather than summarising it afterwards.
| Date | What happened |
|---|---|
| 2 October 2024 | The FDA first determines the tirzepatide shortage is resolved. |
| 22 October 2024 | As part of litigation, that decision is remanded back to the agency to be reconsidered. |
| 19 December 2024 | The FDA re-evaluates and issues a new decision: the shortage is resolved. |
| 18 February 2025 | End of the 60-day window for state-licensed pharmacies compounding under section 503A. |
| 19 March 2025 | End of the 90-day window for outsourcing facilities under section 503B. |
| 5 March 2025 | The district court denies the compounders’ preliminary injunction in Outsourcing Facilities Association v. FDA. |
Compare the two drugs’ deadlines
Tirzepatide’s windows closed on 18 February and 19 March 2025. Semaglutide’s ran to 22 April and 22 May 2025. Anyone who moved from one compounded drug to the other during that period was, briefly, moving toward the one with slightly more time left — which is a strange basis for a medical decision, and worth naming because it happened.
What the FDA has actually recorded
As of 31 May 2026 the agency had received more than 730 reports of adverse events associated with compounded tirzepatide, alongside 990 for compounded semaglutide.
That number is a floor, and the FDA says so
In the agency’s own words, federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to the FDA, so it is likely that adverse events from compounded versions of these drugs are underreported. The count is not an estimate of how often something went wrong. It is a count of what reached the agency through a reporting channel most compounders are not obliged to use.
The agency also notes that many of the reported events look consistent with the side effects of the approved drugs — the digestive reactions set out on our tirzepatide side effects page. It is not always possible to tell whether an event was caused by the drug or by something else. Two categories, though, are specific to the compounded supply chain and could not happen with an approved product.
- Dosing errors, some requiring hospitalisation. The FDA records events tied to patients measuring and self-administering the wrong amount, and in some cases to health professionals miscalculating it. An approved pen delivers a fixed dose; a compounded vial requires someone to draw the right volume from a concentration that varies between pharmacies.
- Products that were never compounded at all. The agency reports an adverse event from a product labelled as compounded tirzepatide, from a pharmacy that had not compounded it — with injection-site redness, swelling, pain and a lump. When the label cannot be trusted, neither the ingredient nor the concentration can be.
The agency separately reports adverse events in people prescribed doses beyond what the approved label carries. We do not publish dosing figures for compounded products for exactly this reason: the numbers vary by pharmacy, and a figure taken from an approved pen does not transfer to a compounded vial.
One thing that is true of semaglutide and not stated of tirzepatide
The best-known criticism of compounded GLP-1s is the salt-form problem: the FDA states that semaglutide sodium and semaglutide acetate are different active ingredients from the one in the approved drug, that it has no information on whether they behave the same way, and that it is not aware of any lawful basis for their use in compounding.
That passage names semaglutide salts. On the page we read, the agency does not make the equivalent statement about tirzepatide salt forms. We are not going to extend it to tirzepatide by implication, because that would be us asserting something the regulator has not.
Why we are being this precise
Most coverage treats compounded semaglutide and compounded tirzepatide as one subject and applies every criticism of one to the other. Some of those criticisms transfer and some are drug-specific. The shortage timeline is genuinely different. The salt-form finding is stated for one and not the other. Blurring them makes the case sound stronger and the reporting worse.
So what is still being sold, and what does it mean
Compounded tirzepatide is still advertised. Compounding remains lawful in narrow circumstances that do not depend on a shortage — a documented clinical need a patient cannot meet with the approved product, for instance — and those circumstances are much narrower than the market that existed in 2024.
The practical question to put to any seller is which of those circumstances applies to you, specifically. A product offered to anyone who fills in a form is not being compounded for an individual clinical need; it is being sold as a cheaper copy, which is the thing the shortage provision used to permit and no longer does.
The price gap that drove the market has also narrowed. Lilly’s own self-pay pricing now starts well below what branded tirzepatide cost when compounding took off — the full ladder is on our cost comparison. That does not make the approved product cheap. It does mean the saving is smaller than the one people remember.
Enforcement actions against compounders and the telehealth companies marketing these products are logged, each with its primary source, on our regulatory tracker.
What this page will not tell you
- Any dose for a compounded product. Concentrations vary by pharmacy, the FDA has logged hospitalisations from dosing errors, and a figure from an approved pen does not transfer.
- Where to buy it. We do not link sellers of unapproved copies of approved drugs.
- Whether your specific prescription is lawful. That depends on facts about you and your prescriber that we cannot see, which is precisely why the question belongs to them.
- That compounded tirzepatide is definitely unsafe. The reported events are largely consistent with the approved drug’s known effects, and causation often cannot be established. The distinct risks are the supply chain and the dose, not the molecule.
Sources and method
- The timeline, the deadlines and the court decision. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, read 5 September 2026 and current as of 1 April 2026. Every date in the table is taken from that page’s own dated entries.
- Adverse event counts, the underreporting statement, dosing errors and the mislabelled product. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, read 5 September 2026 and current as of 1 September 2026. Counts are the agency’s own, as of 31 May 2026.
- What we could not verify. How many compounders are still supplying tirzepatide, on what legal basis each claims to operate, or what any individual pharmacy’s product actually contains. We also cannot say how far the adverse event count understates the real total — only that the FDA states it does.
- Method. Dates and counts come from the FDA’s own pages rather than from law-firm summaries or trade coverage, both of which exist in quantity on this topic and disagree in the detail. Where a finding is stated for semaglutide and not for tirzepatide, this page says so rather than transferring it.
Tirzepatide index → Compounded semaglutide → Regulatory tracker →
FDA pages read 5 September 2026. We recheck this page when the agency updates its GLP-1 concerns page, when the adverse event counts are revised, or when the 503B bulks proposal is finalised.